Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of Oral AMT-101 in Moderate to Severe Ulcerative Colitis
2020-000047-31Phase 2Unknown
- Sponsor
- Applied Molecular Transport
- Start
- Apr 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing AMT-101 with Placebo (2 arms). Status: unknown.
02
Drugs
AMT-101
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2020-000047-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000047-31.